PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsYoichi Nagata, Dihua Yu, Keng‐Hsueh Lan et al.|Cancer Cell|2004Cited by 1.9k
Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast CancerMary Pinder, Sharon H. Giordano, Zhigang Duan et al.|Journal of Clinical Oncology|2007Cited by 630
Current Landscape of Immunotherapy in Breast CancerSylvia Adams, Elizabeth A. Mittendorf, David B. Page et al.|JAMA Oncology|2019Cited by 409
Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and CapecitabineEdith A. Perez, Gabriel N. Hortobágyi, Guillermo Lerzo et al.|Journal of Clinical Oncology|2007Cited by 392
Use and Outcomes of Adjuvant Chemotherapy in Older Women With Breast CancerSharon H. Giordano, James S. Goodwin, Zhigang Duan et al.|Journal of Clinical Oncology|2006Cited by 327